<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03837327</url>
  </required_header>
  <id_info>
    <org_study_id>OVACA-001</org_study_id>
    <nct_id>NCT03837327</nct_id>
  </id_info>
  <brief_title>Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy</brief_title>
  <acronym>VOCAL</acronym>
  <official_title>Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy (VOCAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Venn Biosciences Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Venn Biosciences Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Venn Biosciences Corporation (&quot;InterVenn&quot;) has developed a liquid biopsy that is capable of
      distinguishing benign from malignant masses in women presenting with adnexal (pelvic) masses,
      through a simple blood test. The underlying technology combines mass spectrometry and
      artificial intelligence/machine learning to analyze tumor-associated changes in circulating
      glycoproteins.

      The purpose of this study is to prospectively collect de-identified biological samples and
      data from women with a known pelvic mass, in order to validate ovarian cancer specific
      glycoproteomic signatures in the blood based on histologically confirmed malignancy status of
      the mass.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, international, multi-center, observational study with a goal of
      collecting de-identified samples and data from 1,200 women with a known pelvic mass.
      Participants will consent to baseline and follow-up data and biospecimen collections.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the VOCAL test</measure>
    <time_frame>24-48 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the association of protein and glycoprotein (GP) biomarkers with histological subtypes, stage, treatments and disease free survival (DFS) among woman with ovarian cancer</measure>
    <time_frame>24-48 Months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Adnexal Mass</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Pelvic Mass</condition>
  <arm_group>
    <arm_group_label>Adnexal Mass</arm_group_label>
    <description>Women with an adnexal mass (pelvic mass) as confirmed by imaging</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult women who present with a known adnexal mass as described in the study inclusion and
        exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women age 18 years or older

          -  Able to provide a written informed consent and who understand and agree to all study
             procedures required

          -  A newly diagnosed adnexal mass as confirmed by imaging (computed tomography,
             ultrasonography, or magnetic resonance imaging) prior to enrollment

          -  Planned diagnostic procedure or surgery by the subject's physician to remove adnexal
             masses within 90 days of imaging. (Note that diagnostic procedure typically includes
             biopsy (needle core or laparoscopic-directed), ascites cytology, pleural effusion
             cytology or FNA)

        Exclusion Criteria:

          -  Had/Has a diagnosis of invasive malignancy (exception: non-melanoma skin cancers) in
             the previous 5 years.

          -  Currently receiving or ever received any of the following prior cancer therapies in
             the previous 5 years. This includes curative surgical resection, local or systemic
             chemotherapy, targeted therapy, immunotherapy including cancer vaccines, hormone
             therapy, and/or radiation therapy.

          -  Pregnancy

          -  Current febrile illness

          -  Acute exacerbation or flare of an inflammatory condition requiring escalation in
             therapy

          -  Recipient of organ transplant

          -  Poor health status or unfit to tolerate blood draw

        In addition, this study will include a small subgroup of women with a newly diagnosed
        clinically benign adnexal mass(es) for whom surgery is not planned as determined by the
        treating physician. This subgroup will follow the same exclusion criteria as listed above.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Per eligibility, individuals must have a known adnexal mass (pelvic mass).</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ling Shen, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Venn Biosciences Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ling Shen, Ph.D.</last_name>
    <phone>1-888-706-1670</phone>
    <email>ling@venn.bio</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaitlynn Moser</last_name>
    <phone>1-888-706-1670</phone>
    <email>kaitlynn@venn.bio</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Palo Alto Medical Foundation</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tida Tanti</last_name>
      <phone>408-730-6125</phone>
      <email>tantt@pamf.org</email>
    </contact>
    <investigator>
      <last_name>Albert Pisani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erica Cook, Ph.D</last_name>
      <phone>904-953-3543</phone>
      <email>Cook.Erica@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Tri Dinh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Health University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Morgan, RN</last_name>
      <email>Lisa.Morgan2@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>James Burke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Sudarshan K. Sharma, Ltd. - Gynecologic Oncology</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Miller</last_name>
      <phone>630-601-7707</phone>
      <email>jan.drsharma@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sudarshan Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sultan Ismail</name>
      <address>
        <city>Johor Bahru</city>
        <state>Johor</state>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rathi Raja</last_name>
      <phone>+07-3565155</phone>
      <email>rathi@clinicalresearch.my</email>
    </contact>
    <contact_backup>
      <last_name>Adnin Adawiyah</last_name>
      <phone>+607-3565155</phone>
      <email>adnin.adawiyah@clinicalresearch.my</email>
    </contact_backup>
    <investigator>
      <last_name>Nor Hidayah Binti Yayanto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Seberang Jaya</name>
      <address>
        <city>Seberang Jaya</city>
        <state>Penang</state>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis, Bee Ai Ooi</last_name>
      <phone>+604-3827222</phone>
      <phone_ext>346/ 618</phone_ext>
      <email>francis@clinicalresearch.my</email>
    </contact>
    <investigator>
      <last_name>Salina Bt Sany, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Raja Permaisuri Bainun</name>
      <address>
        <city>Ipoh</city>
        <state>Perak</state>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sivanesan Seevagan</last_name>
      <phone>+60105682316</phone>
      <email>sivanesan@clinicalresearch.my</email>
    </contact>
    <investigator>
      <last_name>Lee Saw Joo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Wanita Dan Kanak-kanak Sabah</name>
      <address>
        <city>Kota Kinabalu</city>
        <state>Sabah</state>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soon Ruey, MD</last_name>
      <email>rueysoon@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Soon Ruey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Medical City</name>
      <address>
        <city>Pasig City</city>
        <state>Metro Manila</state>
        <zip>1605</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Regina Budac</last_name>
      <phone>639178916519</phone>
      <phone_ext>639178916519</phone_ext>
      <email>mbudac@venn.bio</email>
    </contact>
    <contact_backup>
      <last_name>Axel Kornerup</last_name>
      <phone>639178916519</phone>
      <phone_ext>639178916519</phone_ext>
      <email>axel@venn.bio</email>
    </contact_backup>
    <investigator>
      <last_name>Beatrice Tiangco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 8, 2019</study_first_submitted>
  <study_first_submitted_qc>February 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2019</study_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>InterVenn</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Liquid Biopsy</keyword>
  <keyword>Mass Spectrometry</keyword>
  <keyword>Adnexal Mass/ Pelvic Mass</keyword>
  <keyword>Venn Biosciences</keyword>
  <keyword>VOCAL Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

